Photonic monitoring in real time of vascular endothelial growth factor receptor 2 gene expression under relaxin-induced conditions in a novel murine wound model

Annals of the New York Academy of Sciences

Volumn 1041, Issue , 2005, Pages 398-414

  Ryan, Peter L ^a,b,d   Youngblood, Ramey C ^a   Harvill, Jane ^c   Willard, Scott T ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

^c MISSISSIPPI STATE UNIVERSITY   (United States)

^d MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

Photonics; Relaxin; Vascular endothelial growth factor receptor 2; Wound healing

Indexed keywords

LUCIFERASE; RELAXIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIOLUMINESCENCE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HISTOLOGY; MALE; MOUSE; NONHUMAN; PHOTON EMISSION TOMOGRAPHY; PHOTONICS; TRANSGENIC MOUSE; WOUND HEALING;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 23644455511     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1282.061     Document Type: Conference Paper

References (80)

1. LANGER, R. & P. VACANTI. 1993. Tissue engineering. Science 260: 920-926.
2. PIERSCHBACHER, M.D., J.W. POLAREK, W.S. CRAIG, et al. 1994. Manipulation of cellular interactions with biomaterials toward a therapeutic outcome: a perspective. J. Cell. Biochem. 56: 150-154.
3. RYAN, P.L., R.A. FOTY, J. KOHN & M.S. STEINBERG. 2001. Tissue spreading on implantable substrates is a competitive outcome of cell-cell vs. cell-substratum adhesivity. Proc. Natl. Acad. Sci. USA 98: 4323-4327.
4. UNEMORI, E.N., M. LEWIS, J. CONSTANT, et al. 2000. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen. 8: 361-370.
5. DRAPER, B.K., M.K. DAVIDSON & L.B. NANNEY. 2002. MMPs and TIMP-1 are differentially expressed between acute and murine excisional and laser wounds. Lasers Surg. Med. 30: 106-116.
6. KISHIMOTO, J., R. EHAMA, Y. GE, et al. 2000. In vivo detection of human vascular endothelial growth promoter activity in transgenic mouse skin. Am. J. Pathol. 157: 103-110.
7. WEIDNER, N. & J. FOLKMAN. 1996. Tumor vascularity as a prognostic factor in cancer. In Important Advances in Oncology. V.T. DeVita, Jr., S. Hellman & S.A. Rosenberg, Eds.: 167-190. Lippincott-Raven Press. Philadelphia.
8. HOWDIESHELL, T.R., D. CALLAWAY, B.S. WHITNEY, et al. 2001. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J. Surg. Res. 96: 173-182.
9. IGNAR-TROWBRIDGE, D.M., C.T. TENG, K.A. ROSS, et al. 1993. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol. Endocrinol. 7: 992-998.
10. IGNAR-TROWBRIDGE, D.M., M. PIMENTAL, M.G. PARKER, et al. 1996. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase-C orestradiol. Endocrinology 137: 1735-1744.
11. NISSEN, N.N., P.J. POLVERINI, A.E. KOCH, et al. 1998. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am. J. Pathol. 152: 1445-1452.
12. BROWN, L.F., K.T. YEO, B. BERSE, et al. 1992. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176: 1375-1379.
13. NATHAN, C. & M. SPORN. 1991. Cytokines in context. J. Cell Biol. 113: 981-986.
14. CULLINAN-BOVE, K. & R.D. KOOS. 1993. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133: 829-837.
15. TORRY, D.S. & R.J. TORRY. 1997. Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. Am. J. Reprod, Immunol. 37: 21-29.
16. EL-TANANI, M. & C.D. GREEN. 1997. Interaction between estradiol and growth factors in the regulation of specific gene expression in MCF-7 human breast cancer cells. J. Steroid Biochem. Mol. Biol. 60: 269-276.
17. ROCKWELL, L.C., S. PILLAI, E. OLSON & R.D. KOOS. 2002. Inhibition of vascular endothelial growth factor/vascular permeability factor action blocks estrogen-induced uterine edema and implantation in rodents. Biol. Reprod. 67: 1804-1810.
18. HYDER, S.M., Z. NAWAZ, C. CHIAPPETTA & G.M. STANCEL. 2000. Identification of functional response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res. 60: 3183-3190.
19. KOOS, R.D., A.A. KAZI & J.M. JONES. 2005. New insight into the transcriptional regulation of VEGF expression in the endometrium by estrogen and relaxin. Ann. N.Y. Acad. Sci. 1041: 233-247.
20. SHERWOOD, O.D. 1994. Relaxin. In The Physiology of Reproduction, 2nd Ed., Vol. 1. E. Knobil & J.D. Neill, Eds.: 861-1009. Raven Press. New York.
21. LENHART, J.A., P.L. RYAN, K.M. OHLETH & C.A. BAGNELL. 1999. Expression of connexin-26, -32 and -43 gap junction proteins in the porcine cervix and uterus during pregnancy and relaxin-induced growth. Biol. Reprod. 61: 1452-1459.
22. LENHART, J.A., P.L. RYAN, K.M. OHLETH, et al. 2001. Relaxin increases secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9 during uterine and cervical growth and remodeling in the pig. Endocrinology 142: 3941-3949.
23. LENHART, J.A., P.L. RYAN, K.M. OHLETH, et al. 2002. Relaxin increases secretion of tissue inhibitor of matrix metalloproteinase-1 and -2 during uterine and cervical growth and remodeling in the pig. Endocrinology 143: 91-98.
24. RYAN, P.L., D.L. BAUM, J.A. LENHART, et al. 2001. Expression of uterine and cervical epithelial cadherin during relaxin-induced growth in pigs. Reproduction 122: 929-937.
25. FERRARA, N. & T. Davis-Smith. 1997. The biology of vascular endothelial growth factor. Endocr. Rev. 18: 4-25.
26. FERRARA, N., H. CHEN & T. DAVIS-SMYTH. 1998. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4: 336-340.
27. FRASER, H.M., S.E. DICKSON, S.F. LUNN, et al. 2000. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141: 995-1000.
28. SUGINO, N., S. KASHIDA, S. TAKIGUCHI, et al. 2000. Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy. J. Clin. Endocrinol. Metab. 85: 3919-3924.
29. KASHIDA, S., N. SUGINO, S. TAKIGUCHI, et al. 2001. Regulation and role of vascular endothelial growth factor in the corpus luteum during mid-pregnancy in the rat. Biol. Reprod. 64:317-323.
30. AL-ZI'ABI, M.O., E.D. WATSON & H.M. FRASER. 2003. Angiogenesis and vascular endothelial growth factor expression in the equine corpus luteum. Reproduction 125: 259-270.
31. OHLETH, K.M., Q. ZHANG, J.A. LENHART, et al. 1999. Trophic effects of relaxin on reproductive tissue: role of the IGF system. Steroids 64: 634-639.
32. UNEMORI, E.N., M.E. ERICKSON, S.E. ROSCO, et al. 1999. Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cell in vitro and is associated with menometrorrhagia in women. Hum. Reprod. 14: 800-806.
33. PILLAI, S.B., O.D. SHERWOOD & R. KOOS. 2001. Relaxin upregulates rat uterine vascular endothelial growth factor mRNA in vivo. In Relaxin 2000. G.W. Tregear, R. Ivell, R.A. Bathgate & J.D. Wade, Eds.: 109-113. Kluwer Academic Press. The Netherlands.
34. PALEJWALA, S., L. TSENG, A. WOJTCZUK, et al. 2002. Relaxin gene and protein expression and its regulation of procollagenase and vascular endothelial growth factor in human endometrial cells. Biol. Reprod. 66: 1743-1748.
35. HUANG, X., G. ARNOLD, M. LEWIS, et al. 2001. Effect of relaxin on normal and impaired wound healing in rodents. In Relaxin 2000. G.W. Tregear, R. Ivell, R.A. Bathgate & J.D. Wade, Eds. :393-397. Kluwer Academic Press. The Netherlands.
36. PILLAI, S.B., L.C. ROCKWELL, O.D. SHERWOOD & R.D. KOOS. 1999. Relaxin stimulates uterine edema via activation of estrogen receptors: blockade of its effects using ICI 182,780, a specific estrogen receptor antagonist. Endocrinology 140: 2426-2429.
37. YAN, W., P.L. RYAN & C.A. BAGNELL. 2002. Tissue-specific effects of relaxin on the reproductive tract of neonatal pigs: estrogen receptor-dependent and independent actions. Biol. Reprod. 66 (Suppl 1): 202.
38. BAGNELL, C.A., W. YAN, A.A. WILEY & F.F. BARTOL. 2005. Effects of relaxin on neonatal porcine uterine growth and development. Ann. N.Y. Acad. Sci. 1041. In press.
39. GAVINO, E.S. & D.E. FURST. 2001. Recombinant relaxin: a review of pharmacology and potential therapeutic use. BioDrugs 15: 609-614.
40. ROMAN, C.D., H. CHOY, L. NANNEY, et al. 2002. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J. Surg. Res. 105: 43-47.
41. BIGAZZI, M., M.L. BRANDI, G. BANI & T.B. SACCHI. 1992. Relaxin influences the growth of MCF-7 breast cancer cells. Mitogenic and antimitogenic action depends on peptide concentration. Cancer 70: 639-643.
42. SACCHI, T.B., D. BANI, M.L. BRANDI, et al. 1994. Relaxin influences growth, differentiation and cell-cell adhesion of human breast-cancer cells in culture. Int. J. Cancer 57: 129-134.
43. BANI, D., D. FLAGIELLO, M.F. POUPON, et al. 1999. Relaxin promotes differentiation of human breast cancer cells MCF-7 transplanted into nude mice. Virchows Arch. 435: 509-519.
44. BINDER, C., T. HAGEMANN, B. HUSEN, et al. 2002. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Mol. Hum. Reprod. 8: 789-796.
45. SILVERTOWN, J.D., B.J. GEDDES & A.J. SUMMERLEE. 2003. Adenovirus-mediated expression of human prorelaxin promotes the invasive potential of canine mammary cancer cells. Endocrinology 144: 3683-3691.
46. HUNT, T. 1991. Clinical and experimental approaches to dermal and epidermal repair. In Normal and Chronic Wounds. A. Barbul, M. Caldwell, H. Eaglstein, et al., Eds. Wiley Press. New York.
47. VO-DINH, T. 2003. Biomedical photonics: a revolution at the interface of science and technology. In Biomedical Photonics Handbook. T. Vo-Dinh. Ed. :1-18. CRC Press. Washington, DC.
48. WILLARD, S.T., W.J. FAUGHT & L.S. FRAWLEY. 1997. Real-time monitoring of estrogen-regulated gene expression from single, living human breast cancer cells: a new paradigm for the study of molecular dynamics. Cancer Res. 57: 4447-4450.
49. WILLARD, S.T., M.D. AMSTUTZ, E. ABRAHAM, et al. 1999. Simultaneous activity measurements of different hormonal genes in the same, living cell: identification of mammosomatotropes. Am. J. Physiol. 277(6 Pt 1): E1150-E1153.
50. WILLARD, S.T. & L.S. FRAWLEY. 1999. Real-time analysis of dynamic regulatory processes within living endocrine cells. In Recent Development in Comparative Endocrinology and Neurobiology. E.W. Roubos, S.E. Wenderlaar-Bona, H. Vaudry & A. DeLoof, Eds. Shaker Publishing. Maastricht, The Netherlands.
51. ANDERSON, S.L. & S.A. KAY. 1995. Functional dissection of circadian clock- and phytochrome-regulated transcription of the Arabidopsis CAB2 gene. Proc. Natl. Acad. Sci. USA 92: 1500-1504.
52. BRANDES, C., J.D. PLAUTZ, R. STANEWSKY, et al. 1996. Novel features of drosophila period Transcription revealed by real-time luciferase reporting. Neuron 16: 687-692.
53. CONTAG, C.H., P.R. CONTAG, J.I. MULLINS, et al. 1995. Photonic detection of bacterial pathogens in living hosts. Mol. Microbiol. 18: 593-603.
54. CONTAG, C.H., S.D. SPILLAMN, P.R. CONTAG, et al. 1997. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem. Pathobiol. 66: 523-531.
55. YOUNGBLOOD, R.C., T.W. DICKERSON, S.T. WILLARD & P.L. RYAN. 2004. Methoxychlor exposure does not alter vascular endothelial growth factor receptor 2-mediated gene expression in a novel transgenic mouse wound model. FASEB J. Abstr. 787.5.
56. WILLARD, S.T., P.L. RYAN, R. BAILEY, et al. 2002. Development of a novel paradigm for the real-time monitoring of bacterial pathogenicity in swine. J. Anim. Sci. 80 (Suppl 1): 1-433.
57. WILLARD, S.T., R.H. BAILEY, M.L. RYBOLT, et al. 2003. Real-time monitoring of Salmonella in swine: specificity and sensitivity of bacterial detection through the gastrointestinal tracts of juvenile and market weigh pigs: 15 (abstr. 55). ASAS Southern Section, January 31-February 4, 2003. Mobile, AL.
58. ZHANG, N., P.R. CONTAG, A.F. PURCHIO & D.B. WEST. 2004. Tracking angiogenesis induced skin wounding and contact hypersensitivity using a VEGFR-2-luciferase transgenic mouse. Blood 103: 617-626.
59. REGNAULT, T.R., R.J. ORBUS, B. DE VRIJER, et al. 2002. Placental expression of VEGF, OIGF and their receptors in a model of placental insulficiency-intrauterine growth restriction (PI-UGR). Placenta 23: 132-144.
60. SHERWOOID, O.D. & E.M. O'BYRNE. 1974. Purification and characterization of porcine relaxin. Arch. Biochem. Biophys. 73: 479-485.
61. WIQVIST N. & K.G. PAUL. 1958. Inhibition of spontaneous uterine motility in vitro as a biological assay of relaxin. Acta Endocrinol (Copenh.) 29: 135-146.
62. PORTER, D.G., P.L. RYAN & L. NORMAN. 1992. Lack of effect of oxytocin output from the porcine neural lobe in vitro or in lactating sows in vivo. J. Reprod. Fertil. 96: 251-260.
63. VOOIJIS, M., J. JONKERS, S. LYONS & A. BERNS. 2002. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res. 62: 1862-1867.
64. FORESTA, C., A. BETTELLA, C. VIANZI, et al. 2004. A novel circulating hormone of testis origin in humans. J. Clin. Endocrinol. Metab. 89: 5952-5958.
65. SAMUEL, C.S., H. TIAN, L. ZHAO & E.P. AMENTO. 2003. Relaxin is a key mediator of prostate growth and male reproductive tract development. Lab. Invest. 83: 1055-1067.
66. THOMPSON, V., T. WHITMORE, D. BRADLEY, et al. 2005. Relaxin is upregulated during prostate cancer progression to androgen independence and is repressed by androgens. Ann. N.Y. Acad. Sci. 1041.
67. SHIROTA, K., K. TATEISHI, M. EMOTO, et al. 2005. Relaxin-induced angiogenesis in ovary contributes to follicle development. Ann. N.Y. Acad. Sci. 1041: 144-146
68. CONTAG, P.R., L.N. OLOMU, D.K. STEVENSON & C.H. CONTAG. 1998. Bioluminescent indicators in living mammals. Nat. Med. 4: 245-247.
69. SKINNER, H.D., J.Z. ZHENG, J. FANG, et al. 2004. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor-1a, HDM2, and p70S6k1 in response to phosphatidylinositol 3-kinase/AKT signaling. J. Biol. Chem. 279:45643-45651.
70. GUNNERSON, J.M., P.J. ROCHE, G.W. TREGEAR & R.J. CRAWFORD. 1995. Characterization of human relaxin gene regulation in the relaxin-expressing human prostate adenocarcinoma cell line LNCaP.FGC. J. Mol. Endocrinol. 15: 153-166.
71. BINDER, C., A. SIMON, L. BINDER, et al. 2004. Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res. Treat. 87: 157-166.
72. IVELL, R. & A. EINSPANIER. 2002. Relaxin peptides are new global players. Trends Endocrinol. Metab. 13: 343-348.
73. IVELL, R. & R.A. BATHGATE. 2002. Reproductive biology of the relaxin-like factor (RLF/INSL3). Biol. Reprod. 67: 699-705.
74. KAWAMURA, K., J. KUMAGAI, S. SUDO, et al. 2004. Paracrine regulation of mammalian oocyte maturation and male germ cell survival. Proc. Natl. Acad. Sci. USA 101: 7323-7328.
75. IVELL R. & S. HARTUNG. 2003. The molecular basis of cryptorchidism. Mol. Human Reprod. 9: 175-181.
76. FERLIN, A., M. SIMONATO, L. BATOLONI, et al. 2003. The INSLs-LGR8/GREAT ligand-receptor pair in human cryptorchidism. J. Clin. Endocrinol. Metab. 88: 4273-4279.
77. BAUSERO, P.M., H. BEN-MAHDI, J.P. MAZUCATELLI, et al. 2000. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am. J. Physiol. Heart Circ. Physiol. 279: H2033-H2042.
78. RYAN, H.E., M. POLONI, W. MCNULTY, et al. 2000. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 60: 4010-4015.
79. ELSON, D.A., H.E. RYAN, J.W. SNOW, et al. 2000. Coordinate up-regulation of hypoxia inducible factor (HIF-1) α and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res. 60: 6189-6195.
80. LIU, X.H., A. KIRSCHENBAUM, S. YAO, et al. 1999. Upregulation of vascular endothelial growth factor by cobalt chloride-stimulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin. Exp. Metastasis 17: 687-694.